Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Karuna Therapeutics, Inc. (KRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023 144 Form 144 - Report of proposed sale of securities:
10/03/2023 4 Brown Jason Parker (CFO) has filed a Form 4 on Karuna Therapeutics, Inc.
Txns: Granted 4,496 shares @ $0
Granted 7,696 options to buy @ $169.09, valued at $1.3M
10/03/2023 3 Brown Jason Parker (CFO) has filed a Form 3 on Karuna Therapeutics, Inc.
08/24/2023 4 Ignelzi Troy A. (CFO) has filed a Form 4 on Karuna Therapeutics, Inc.
Txns: Sold 80 shares @ $173.64, valued at $13.9k
Sold 855 shares @ $174.88, valued at $149.5k
Sold 505 shares @ $175.59, valued at $88.7k
Sold 60 shares @ $176.6, valued at $10.6k
Exercised 1,500 options to buy @ $9.2, valued at $13.8k
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 4 Brannan Stephen K. (Chief Medical Officer) has filed a Form 4 on Karuna Therapeutics, Inc.
Txns: Sold 2,395 shares @ $179.53, valued at $430k
Sold 1,355 shares @ $180.93, valued at $245.2k
Sold 1,250 shares @ $181.5, valued at $226.9k
Exercised 2,500 options to buy @ $5.45, valued at $13.6k
Exercised 5,000 options to buy @ $131.64, valued at $658.2k
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates On track to submit New Drug Application for KarXT in schizophrenia with the U.S. FDA in the third quarter of 2023, with a product launch in the second half of 2024, assuming approval Initiated the Phase 3 ADEPT-3 open label extension trial in the third quarter of 2023, and on track to commence the Phase 3 ADEPT-2 trial in the second half of 2023 Announced the appointment of Jonathan Rosin to Chief Human Resources Officer and the promotion of Jason Brown to Chief Financial Officer $1.4 billion in cash expected to fund operations through 2026 Conference call and webcast to take place today at 8:00 a.m. ET"
08/02/2023 4 JONAS JEFFREY M (Director) has filed a Form 4 on Karuna Therapeutics, Inc.
Txns: Sold 3,399 shares @ $194.78, valued at $662.1k
Sold 6,301 shares @ $195.61, valued at $1.2M
Sold 3,110 shares @ $196.59, valued at $611.4k
Sold 400 shares @ $197.66, valued at $79.1k
Sold 600 shares @ $198.41, valued at $119k
Exercised 13,810 options to buy @ $7.27, valued at $100.4k
07/07/2023 SC 13G/A BlackRock Inc. reports a 5% stake in KARUNA THERAPEUTICS INC
07/05/2023 4 OLSON LAURIE J (Director) has filed a Form 4 on Karuna Therapeutics, Inc.
Txns: Sold 600 shares @ $215.4, valued at $129.2k
Sold 400 shares @ $216.03, valued at $86.4k
Exercised 1,000 options to buy @ $84.86, valued at $84.9k
07/05/2023 4 JONAS JEFFREY M (Director) has filed a Form 4 on Karuna Therapeutics, Inc.
Txns: Sold 234 shares @ $214.61, valued at $50.2k
Sold 7,966 shares @ $215.91, valued at $1.7M
Sold 3,201 shares @ $216.78, valued at $693.9k
Sold 2,409 shares @ $217.82, valued at $524.7k
Exercised 13,810 options to buy @ $7.27, valued at $100.4k
07/03/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 SC 13G Capital International Investors reports a 10.3% stake in Karuna Therapeutics, Inc.
05/25/2023 4 Ignelzi Troy A. (CFO) has filed a Form 4 on Karuna Therapeutics, Inc.
Txns: Sold 724 shares @ $221.28, valued at $160.2k
Sold 2,093 shares @ $222.24, valued at $465.1k
Sold 3,309 shares @ $223.21, valued at $738.6k
Sold 1,070 shares @ $224.19, valued at $239.9k
Sold 1,022 shares @ $225.19, valued at $230.1k
Sold 782 shares @ $225.93, valued at $176.7k
Exercised 9,000 options to buy @ $9.2, valued at $82.8k
05/23/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/18/2023 144 Form 144 - Report of proposed sale of securities:
04/05/2023 4 OLSON LAURIE J (Director) has filed a Form 4 on Karuna Therapeutics, Inc.
Txns: Sold 1,000 shares @ $181.02, valued at $181k
Exercised 1,000 options to buy @ $84.86, valued at $84.9k
03/22/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Karuna Therapeutics, Inc.Common Stock, par value $0.0001 per share _________ Underwriting Agreement March 21, 2023 Goldman Sachs & Co. LLCJ.P. Morgan Securities LLC Morgan Stanley & Co. LLC As representatives of the several Underwritersnamed in Schedule I hereto c/o Goldman Sachs & Co. LLC200 West StreetNew York, New York 10282",
"Registration Statement”) filed on July 2, 2020 with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended , relating to the registration of the offer by Karuna Therapeutics, Inc., a Delaware corporation of an indeterminate number of any combination of securities of the types specified therein. The Registration Statement became effective upon filing with the Commission. Reference is made to our opinion letter dated July 2, 2020 and included as Exhibit 5.1 to the Registration Statement. We are delivering this supplemental opinion letter in connection with the prospectus supplement (the “Prospectus Supplement",
"Karuna Therapeutics Announces Proposed Public Offering of Common Stock",
"Karuna Therapeutics Announces Pricing of Public Offering of Common Stock"
03/22/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/20/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/20/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 4 Brannan Stephen K. (Chief Medical Officer) has filed a Form 4 on Karuna Therapeutics, Inc.
Txns: Sold 5,000 shares @ $189.51, valued at $947.6k
Exercised 5,000 options to buy @ $5.45, valued at $27.3k
02/23/2023 4 Ignelzi Troy A. (CFO) has filed a Form 4 on Karuna Therapeutics, Inc.
Txns: Sold 6,000 shares @ $190.01, valued at $1.1M
Exercised 6,000 options to buy @ $9.2, valued at $55.2k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy